Monograph: Electrodiagnostic Approach to Defects of Neuromuscular Transmission
Abstract
Neuromuscular junction (NMJ) disorders such as myasthenia gravis, Lambert-Eaton myasthenic syndrome, and botulism are characterized by impaired synaptic transmission leading to weakness. This review examines the electrodiagnostic evaluation of these conditions, emphasizing the importance of techniques such as repetitive nerve stimulation (RNS) and single-fiber electromyography (SFEMG) for confirming the diagnosis and distinguishing presynaptic from postsynaptic defects. The reduced safety factor of neuromuscular transmission (NMT) in postsynaptic disorders produces a decrement in compound muscle action potential (CMAP) amplitude and area with low-frequency stimulation, whereas presynaptic disorders show small baseline CMAPs that increase markedly in amplitude and area (postactivation facilitation) after brief exercise or during high-frequency stimulation. SFEMG, the most sensitive test of abnormal NMT, measures neuromuscular jitter—temporal variability in action potential generation—and also reflects a compromised safety factor. Fiber density remains normal in primary NMJ disorders, distinguishing them from conditions with neuropathic reinnervation, such as motor neuron disease. Proper performance and interpretation of these electrodiagnostic studies are essential for accurate diagnosis, assessment of disease severity, and guiding management of NMJ disorders.
Objectives: The objectives of this activity are to: 1) Understand the anatomy and physiology of the neuromuscular junction. 2) Understand the role of electrodiagnostic testing in diagnosing neuromuscular junction disorders. 3) Learn how to identify and prevent artifacts in electrodiagnostic testing.
ACCREDITATION STATEMENT
The AANEM is accredited by the American Council for Continuing Medical Education (ACCME) to providing continuing education for physicians. AANEM designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE INFORMATION
The author served on an advisory board committee for Johnson & Johnson, and the author's previous institution received grant money from Grifols. In accordance with ACCME requirements, all relevant financial relationships have been mitigated.
Jonathan M. Morena